title: [Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection].
abstract: OBJECTIVE
  Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea.
  
  
  METHODS
  The subjects consisted of 201 patients infected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared.
  
  
  RESULTS
  The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth triple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05).
  
  
  CONCLUSIONS
  Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.
authors.affiliation: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
authors.forename: Jae Hee
authors.initials: JH
authors.lastname: Cheon
authors.forename: Nayoung
authors.initials: N
authors.lastname: Kim
authors.forename: Dong Ho
authors.initials: DH
authors.lastname: Lee
authors.forename: Jin-Wook
authors.initials: JW
authors.lastname: Kim
authors.forename: Jin-Hyeok
authors.initials: JH
authors.lastname: Hwang
authors.forename: Young Soo
authors.initials: YS
authors.lastname: Park
authors.forename: Jung Mogg
authors.initials: JM
authors.lastname: Kim
authors.forename: Seong O
authors.initials: SO
authors.lastname: Suh
authors.forename: Hyun Chae
authors.initials: HC
authors.lastname: Jung
authors.forename: In Sung
authors.initials: IS
authors.lastname: Song
mesh_terms: D000328:Adult; D000368:Aged; D000863:Antacids / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001372:Aza Compounds / Q000008:administration & dosage*; D001729:Bismuth / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D054328:Proton Pump Inhibitors; D011804:Quinolines / Q000008:administration & dosage*
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D054328:Proton Pump Inhibitors; D011804:Quinolines; D001729:Bismuth; D000077266:Moxifloxacin